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Abstract
Background: Autosomal dominant tubulointerstitial kidney disease (ADTKD) caused by mutations in the UMOD
gene (ADTKD-UMOD) is considered rare and often remains unrecognised. We aimed to establish the prevalence of
genetic kidney diseases, ADTKD and ADTKD-UMOD in adult chronic kidney disease (CKD) patients, and to
investigate characteristic features.
Methods: We sent questionnaires on family history to all patients with CKD stages 3–5 in our tertiary renal centre
to identify patients with inherited renal disease. Details on clinical and family history were obtained from patient
interviews and clinical records. Sanger sequencing of the UMOD gene was performed from blood or saliva samples.
Results: 2027 of 3770 sent questionnaires were returned. 459 patients reported a family history, which was consistent
with inherited kidney disease in 217 patients. 182 non-responders with inherited kidney diseases were identified
through a database search. Of these 399 individuals, 252 had autosomal dominant polycystic kidney disease (ADPKD),
28 had ADTKD, 25 had Alports, and 44 were unknown, resulting in 11% of CKD 3–5 patients and 19% of end-stage
renal disease patients with genetic kidney diseases. Of the unknown, 40 were genotyped, of whom 31 had findings
consistent with ADTKD. 30% of unknowns and 39% of unknowns with ADTKD had UMOD mutations. Altogether, 35
individuals from 18 families were found to have ten distinct UMOD mutations (three novel), making up 1% of patients
with CKD 3–5, 2% of patients with end-stage renal disease, 9% of inherited kidney diseases and 56% with ADTKD.
ADTKD-UMOD was the most common genetic kidney disease after ADPKD with a population prevalence of 9 per
million. Less proteinuria and haematuria, but not hyperuricaemia or gout were predictive of ADTKD-UMOD. The main
limitations of the study are the single-centre design and a predominantly Caucasian population.
Conclusions: The prevalence of genetic kidney diseases and ADTKD-UMOD is significantly higher than previously
described. Clinical features poorly predicted ADTKD-UMOD, highlighting the need for genetic testing guided by family
history alone.
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Background
Autosomal dominant tubulointerstitial kidney disease
(ADTKD) is a rare genetic kidney disease. ADTKD
caused by mutations in the UMOD gene (ADTKD-U-
MOD) is the most common form of ADTKD [1, 2].
Other gene mutations causing ADTKD include mucin 1
(MUC1), hepatocyte nuclear factor 1 beta (HNF1b),
renin (REN), and the alpha subunit of the endoplasmic re-
ticular membrane translocon (SEC61A1) [3–7]. Previously
known as familial juvenile hyperuricaemic nephropathy
(FJHN) and uromodulin associated kidney disease
(UAKD), ADTKD-UMOD is characterised by early onset
hyperuricaemia and gout affecting both sexes, and the
development of insidious renal failure with tubulointersti-
tial disease [8]. These disorders characteristically do not
feature haematuria or proteinuria. Patients usually develop
end stage renal disease (ESRD) between the third and
sixth decade of life. However, clinical features are variable
and hyperuricaemia and gout may be absent [9]. Some
patients are found to have medullary renal cysts [10]. It
has been shown that pathogenic UMOD mutations cause
protein misfolding, retention in the endoplasmic
reticulum (ER) and mistargeting of uromodulin in the
thick ascending limb of Henle, resulting in tubulointersti-
tial damage through ER stress and reduced urinary uro-
modulin excretion [11–13]. A recent knock-in mouse
model harbouring a human mutation has given insight
into the pathophysiology of ADTKD-UMOD [14].
Inherited interstitial kidney diseases are underrecog-
nised and underreported due to their lack of distinctive
clinical or diagnostic histological features, lack of phys-
ician awareness and incomplete acquisition of family his-
tories [15]. Registry data reliant on accurate diagnostic
coding is known to be incomplete [16], and there is a
paucity of information on the prevalence of genetic kid-
ney diseases. Published studies suggest a prevalence of
polycystic kidney disease of 5–11% and of other familial
nephropathies of 4–6% amongst ESRD patients [17–21].
Registry figures for the latter are even lower between 2
and 3% [22, 23]. The UK’s National Rare Disease Regis-
try (RaDaR) lists 115 patients with ADTKD for a popu-
lation of 65 million, resulting in a prevalence of 1.8 per
million [24]. The published population prevalence of
ADTKD-UMOD from a single Austrian study was 1.7
per million [25].
Preliminary data from our tertiary renal and trans-
plant centre with a catchment population of 2 million
had suggested that this was a gross underestimate,
with a much higher in centre prevalence of
ADTKD-UMOD [26]. Therefore we aimed to establish
the prevalence of ADTKD-UMOD and genetic kidney
diseases as a whole, and to investigate clinical and




Questionnaires were sent to all patients in CKD stages
3–5 and all transplant recipients registered on the elec-
tronic database Proton. The one-page questionnaire
asked patients to record any family members with
kidney disease, their relation to the patient, their renal
diagnosis (if known), the patient’s own diagnosis, and
their willingness to be contacted about the study
(Additional File 1). Genetic kidney diseases of interest to
this study were defined as monogenic diseases rather
than disorders of polygenic risk alleles predisposing to
kidney disease. Positive responses were reviewed.
Non-responders with CKD stages 3–5 with a family
history of renal disease were identified through a
search of diagnostic codes, electronic patient letters
and through their nephrologists. Patient letters were
reviewed for the presence of a positive family history
for all non-responders with missing diagnostic codes,
diagnostic codes 0 (chronic renal failure, aetiology un-
certain), 30 (interstitial nephritis due to other cause,
or unspecified), 40 (cystic kidney disease, type un-
specified), 43 (medullary cystic kidney disease includ-
ing nephronophthisis), 49 (cystic kidney disease, other
specified type), 50 (hereditary/familial nephropathy
type unspecified), 59 (hereditary nephropathy, other
specified type) and 92 (gout).
If a genetic kidney disease was likely as suggested by a
relative with a compatible diagnosis, patients were in-
vited to participate in the study.
Patients gave written informed consent before provid-
ing a blood or saliva sample. Clinical data and pedigrees
were recorded from patient interviews and clinical
records.
Genetic investigations
Genomic DNA extraction from whole blood was per-
formed by QIAamp DNA Blood Midi kit (Qiagen, Venlo,
Netherlands) or the salting out method [27], and from
saliva by Oragene kit (DNA Genotek, Ontario, Canada).
Exons 3 to 5 of the UMOD gene were sequenced in an
ABI 3130 XL Genetic Analyser. In three families, other
UMOD exons had been sequenced beforehand by cus-
tom gene panel [6] or Sanger sequencing [13] at the In-
stitute for Inherited Metabolic Disorders in Prague.
Sequencing files were analysed by the software “Muta-
tion Surveyor” (SoftGenetics, State College, PA, USA)
using Genbank reference sequence NM_003361.3. Gen-
etic variants were annotated with variant coding effects,
predictive metrics of deleteriousness Polyphen-2 [28],
and SIFT [29], and minor allele frequencies from the
1000 Genomes Project (1KG) [30], Exome Sequencing
Project (ESP) [31] and Exome Aggregation Consortium
(ExAC) [32] with ANNOVAR v2013Aug23 [33].
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Exome sequencing of six samples from participants
with a particularly strong family history was performed
using the exome capture kits Agilent SureSelect v.5.0
(51 Mb) and Agilent Sure Select All Exon and sequenced
on the HiSeq 2000 Sequencer or Illumina Genome
Analyzer IIx. Reads were aligned to the reference gen-
ome (GRCh37) using Novoalign (Novocraft, 2010). Vari-
ants were called using GATK and annotated using
Annovar.
Clinical confirmatory sequencing was performed using
fresh blood samples.
Features associated with ADTKD-UMOD
Clinical and biochemical features were compared between
patients with pathogenic UMOD mutations and the
remaining cohort. Statistical significance was determined
by the χ2 test, Fisher’s Exact test, Mann-Whitney-U test,
or Kruskall-Wallis test, as appropriate, using SPSS version
24 (IBM, Armonk, NY).
Results
Patient ascertainment
3770 questionnaires on family history were sent to all pa-
tients (96% Caucasian) in CKD stages 3 to 5 and all trans-
plant recipients registered on our electronic renal
database. 2027 responses were received, corresponding to
a response rate of 53.8%. 459 patients (22.6% of re-
sponders) reported a family history of kidney disease. Of
these, in 217 patients (47%) an underlying genetic kidney
disease was likely, in 184 patients (40%), the respective
renal diagnoses for patients and relatives were apparently
unrelated (e.g. diabetic nephropathy and renal cancer),
and in 58 patients (13%) not enough information was
available to allow an assessment (Fig. 1). The question-
naire study resulted in the identification of an additional
54 patients with genetic kidney diseases for whom either
the diagnosis or coding were incomplete. Responders with
an underlying genetic kidney disease were statistically
younger (median age 59 versus 64 years with a reported
family history and 68 years for all responders, p < 0.001,
Kruskall-Wallis = 99.057), more likely to have ESRD (67%
versus 38% for all responders, p < 0.001, χ2 = 79.827), and
female (55% versus 41%, p < 0.001, χ2 = 79.827).
Amongst the non-responders, an additional 182 pa-
tients with genetic kidney diseases were identified
through their nephrologists, a review of coded diagnoses
and diagnoses extracted from clinic letters (Fig. 1). 38 of
61 patients (62%) with ADTKD had returned the ques-
tionnaire, and of these, 30 (79%) would have been identi-
fied by database screening.
Prevalence of genetic kidney diseases
Of the total 399 patients with genetic kidney diseases,
252 (63%) had autosomal dominant polycystic kidney
disease (ADPKD), and 147 (37%) had other genetic kidney
diseases. For the latter cohort, the most common diagno-
ses were unknown familial nephropathies, followed by
ADTKD, Alport disease, familial focal segmental glomeru-
losclerosis (FSGS) or steroid resistant nephrotic syndrome
(SRNS), and familial reflux nephropathy.
The prevalence rate of genetic kidney diseases was
11% for all CKD 3+ patients and 19% for patients with
ESRD, with very similar rates obtained for responders
and all patients (Table 1), confirming the effective unco-
vering of patients with genetic kidney diseases amongst
the non-responders. Genetic kidney diseases other than
ADPKD had a prevalence rate of 4% amongst CKD pa-
tients and 8% amongst ESRD patients.
UMOD mutations
Sanger sequencing of exons 3–5 of the UMOD gene was
performed on DNA samples from 113 participants with
no established conflicting genetic diagnosis. Six partici-
pants from five families with a strong family history of
renal disease underwent exome sequencing before
Sanger sequencing. In three families this identified
pathogenic UMOD mutations within exons 3–5 which
were confirmed to segregate with disease by Sanger
sequencing.
Ten distinct heterozygous gene mutations were found
in 35 participants from 18 families, all Caucasian
(Table 2). Two individuals from two families carried the
non-disease causing variant p.(Thr62Pro). We achieved
a new diagnosis of ADTKD-UMOD in 11 individuals
from seven families and confirmed ADTKD-UMOD in
24 individuals from eleven families.
28 patients had pre-existing diagnoses within the
spectrum of ADTKD, 44 had unknown familial nephrop-
athies, of whom 33 had clinical features consistent with
ADTKD. Of the 44 unknown, 40 were genotyped. 30%
(13/44) of the unknowns, 39% (13/33) of unknowns with
ADTKD, and 57% (35/61) of all ATKD patients had
UMOD mutations (Fig. 1). Altogether ADTKD-UMOD
made up 1% (35/3770) of CKD 3+, 2% (29/1425) of
ESRD, 9% (35/399) of inherited kidney diseases (24%
without ADPKD), and 57% (35/61) of ADTKD. ADTKD
made up 2% (61/3770) of CKD3+, 3% of ESRD (41/
1425) and 15% (61/399) of inherited kidney diseases
(42% without ADPKD).
Seven of the ten distinct gene mutations were pub-
lished mutations and listed in the Wake Forest Inherited
Kidney Disease Database for uromodulin associated kid-
ney disease [34] (variant p.(Thr62Pro) was listed as clin-
ically silent), and three of these were also present in the
Human Gene Mutation Database (Table 3) [35].
The three novel mutations were classed as probably
pathogenic in view of the patients’ clinical phenotype,
family history, high predictive metrics of deleteriousness
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with Polyphen scores of 1 and SIFT scores of 0, and
absence from the large population sequencing data-
bases 1000 Genomes (1KG), Exome Sequencing
Project (ESP) and Exome Aggregation Consortium
(ExAC).
Mutation c.263G > T predicting UMOD substitution
p.(Gly88Val) occurred in a patient with a diagnosis of
medullary cystic kidney disease. A UMOD mutation
had been found in a relative from another region, al-
though the exact nature of the relative’s mutation was
Fig. 1 Diagnostic Pathway
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unknown. Mutation c.614 T > C predicting p.(Phe205-
Ser) was found in a participant with a strong family
history of autosomal dominant kidney disease. As the
majority of affected relatives lived abroad it was not
possible to perform segregation analysis of the vari-
ant. Mutation c.860G > A predicting p.(Cys287Tyr)
was found in a patient with a diagnosis of FJHN and
a strong family history of kidney disease. The same
mutation was confirmed in her teenage daughter, who
has hyperuricaemia.
Clinical features
Clinical and biochemical parameters were compared be-
tween patients with non-polycystic genetic kidney dis-
eases with and without UMOD mutations (Table 4), and
between ADTKD patients with and without UMOD mu-
tations (Table 5). After Bonferroni correction, patients
with ADKTD-UMOD had lower protein creatinine ra-
tios (p < 0.001), and a reduced presence of proteinuria
(p < 0.001) and haematuria (p < 0.001) compared to all
genotyped patients with genetic kidney diseases. There
was no statistically significant association between
ADTKD-UMOD and age at presentation, age at renal
replacement therapy (RRT), gout, allopurinol use, hyper-
tension, hyperuricaemia, uric acid levels, electrolyte ab-
normalities, anaemia, renal cysts, or renal size. There
was a trend for a younger age at presentation for
ADTKD-UMOD patients compared to ADTKD-NOS
(ADTKD-not otherwise specified, i.e. UMOD negative),
which lost its statistical significance after Bonferroni
correction.
Final prevalence figures
In addition to establishing 13 new diagnoses of
ADTKD-UMOD, we identified six additional patients
with Alport disease through a targeted next generation
sequencing panel of patients with FSGS/SRNS as de-
scribed previously [36]. In total, we established 35 diag-
noses of ADTKD-UMOD in our study population, and
31 diagnoses of Alport disease. 26 patients from 13 fam-
ilies had ADTKD of unknown genotype, and 31 patients
were left with an undiagnosed genetic kidney disease.
By counting each family only once, we calculated the
population prevalence of ADTKD-UMOD conservatively
at 9 per million, and of ADTKD at 16 per million.
Discussion
This study identified a higher prevalence of genetic kid-
ney diseases than previously described and found
ADTKD-UMOD to be the most common genetic kidney
disease after ADPKD.
Previous prevalence studies on genetic kidney diseases
have largely relied on registry data and have rarely made
use of genetic testing. The first study to highlight the
importance of familial kidney diseases identified a preva-
lence of familial glomerulonephritides of 10% of all
forms of glomerulonephritis in Germany [37]. An Irish
cross-sectional study reported a prevalence of familial
kidney diseases other than ADPKD of 4% for transplant
and 5% for haemodialysis patients [17]. Similarly, 4% of
ESRD patients in Newfoundland [18] and 6% of Swedish
transplant patients [20] were reported to have a familial
kidney disease other than ADPKD. A single-centre study
from Italy established a prevalence of 4% of rare genetic
disorders amongst transplant recipients with an un-
known diagnosis [21]. A recent registry study of CKD
patients of any stage from Australia found a prevalence
of genetic kidney diseases other than ADPKD of 6%
[38], but controversially included physician-ascertained
congenital abnormalities of the kidneys and urinary tract
(CAKUT) which constituted two thirds of genetic
diagnoses.
Our prevalence of 8% for non-polycystic genetic kid-
ney diseases amongst ESRD patients is higher than the
previously published figures. We are the first to give an
estimate of genetic kidney diseases amongst patients
with CKD3+ of 4% (11% including ADPKD). This figure
is lower than in our end-stage population consistent
with our finding that patients with genetic kidney dis-
eases were more likely to reach ESRD than patients with
other diagnoses, despite being younger.
Our UMOD mutation analysis revealed 10 distinct
pathogenic mutations in 35 participants from 18 fam-
ilies. Three mutations were unpublished. The presence
of affected relatives with a UMOD mutation in two of
the families makes it highly likely that these are patho-
genic mutations, even in the absence of a complete seg-
regation analysis. The third kindred had a strong family
history of autosomal dominant kidney disease consistent
with ADTKD-UMOD. The maximally deleterious Poly-
phen and SIFT scores of all three mutations and their
Table 1 Prevalence rates for genetic kidney diseases (GKD) in CKD cohort
Responders All Patients Responders with ESRD All patients with ESRD
All GKD 217/2027 = 10.7% 399/3770 = 10.6% 144/772 = 18.7% 269/1425 = 18.9%
ADPKD 140/2027 = 6.9% 252/3770 = 6.7% 88/772 = 11.4% 161/1425 = 11.3%
Other GKD (non-ADPKD) 77/2027 = 3.8% 147/3770 = 3.9% 56/772 = 7.3% 108/1425 = 7.6%
ADTKD 39/2027 = 1.9% 61/3770 = 1.6% 31/772 = 4.0% 44/1425 = 3.1%
ADTKD-UMOD 19/2027 = 0.9% 35/3770 = 0.9% 18/772 = 2.3% 27/1425 = 1.9%
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absence from the large population databases 1KG,
ESP and ExAC lend further support to this interpret-
ation. Mutation c.184A > C predicting p.(Thr62Pro)
was considered clinically silent as reported in
Ensembl (SNP rs143248111) and in the Wake Forest
Registry, and supported by its presence in the
non-disease databases ESP and ExAC. Complete seg-
regation analysis in the families was not possible but
several affected relatives had variant p.(Thr62Pro)
confirmed at another centre.
Table 2 UMOD mutation table
Study Number Mutation (reference
sequence NM_003361.3)
Protein Alteration Family history
of renal disease
Diagnosis of FJHN/ ADTKD-
UMOD prior to study
Age at RRT Hyperuricaemia Gout
FN68 301a c.202G > A p.(Glu68Lys) Yes Yes 41 No No
FN9 304a c.263G > T p.(Gly88Val) Yes Yes 44 Yes No
FN2 301 c.272-274del p.(Ser91del) Yes Yes 39 Yes Yes
FN2 302 c.272-274del p.(Ser91del) Yes Yes 45 Yes No
FN2 303a c.272-274del p.(Ser91del) Yes Yes 58 Yes No
FN3 301a c.272-274del p.(Ser91del) Yes No Yes No
FN3 305a c.272-274del p.(Ser91del) Yes No 64 No
FN3 409a c.272-274del p.(Ser91del) Yes No 38 No No
FN26 301a c.272-274del p.(Ser91del) Yes No 56 Yes No
FN45 304a c.272-274del p.(Ser91del) Yes Yes 45 Yes No
FN45 404a c.272-274del p.(Ser91del) Yes Yes 51 No Yes
FN45 405a c.272-274del p.(Ser91del) Yes Yes 37 No
FN65 201 c.272-274del p.(Ser91del) Yes Yes 66 No
FN65 202 c.272-274del p.(Ser91del) Yes Yes 59 No
FN65 203a c.272-274del p.(Ser91del) Yes Yes 59 Yes No
FN65 301 c.272-274del p.(Ser91del) Yes Yes Yes Yes
FN65 401 c.272-274del p.(Ser91del) Yes Yes 47 Yes Yes
FN65 402 c.272-274del p.(Ser91del) Yes Yes Yes Yes




















Yes Yes 49 Yes No
FN20 302 c.443G > A p.(Cys148Tyr) Yes Yes 50 Yes Yes
FN20 403 c.443G > A p.(Cys148Tyr) Yes Yes Yes No
FN64 303a c.614 T > C p.(Phe205Ser) Yes No 42 Yes Yes
FN23 302 c.629G > A p.(Gly210Asp) Yes No 36 Yes Yes
FN23 303 c.629G > A p.(Gly210Asp) Yes No 46 No
FN27 304a c.688 T > C p.(Trp230Arg) Yes No 63 Yes Yes
FN27 306a c.688 T > C p.(Trp230Arg) Yes No Yes Yes
FN28 302 c.688 T > C p.(Trp230Arg) Yes Yes 57 Yes Yes
FN28 401a c.688 T > C p.(Trp230Arg) Yes Yes Yes Yes
FN7 305 c.860G > A p.(Cys287Tyr) Yes Yes 27 Yes Yes
FN35 403a c.917G > A p.(Cys287Tyr) Yes Yes 57 Yes No
FN35 501a c.917G > A p.(Cys287Tyr) Yes Yes 42 Yes Yes
RRT renal replacement therapy, FJHN familial juvenile hyperuricaemic nephropathy
aclinically confirmed
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We are likely to have underestimated the true preva-
lence of ADTKD-UMOD since we were only able to
screen those patients with significant CKD who had
been referred to tertiary renal services and their rela-
tives. Conversely, patients with an obvious inherited kid-
ney disease may have been referred to our service earlier
than other patients in CKD stage 3. This could theoret-
ically have led to an overestimation of ADTKD as a pro-
portion of CKD patients, but it could not have
overestimated the total prevalence figures based on the
catchment population. Furthermore, when taking other
possible sources of under-ascertainment into account,
an overestimation of the prevalence of ADTKD appears
very unlikely.
Having only sequenced exons 3–5 in the majority of
patients [9, 39], we may have missed mutations in the
remaining seven exons of the UMOD gene, where only
5% of mutations are expected to occur [40].
The incomplete response rate of 53.8% was a recog-
nised source of incomplete ascertainment. To compen-
sate for this, we undertook a comprehensive database
search of all non-responders with missing and/or suspi-
cious diagnostic codes. This search would have captured
79% of responders with ADTKD had they not
responded. Furthermore, the prevalence rates established
for responders and the cohort as a whole were very simi-
lar, indicating that any bias inherent in the different
forms of patient ascertainment was likely limited, al-
though a remaining degree of incomplete ascertainment
remained.
A limitation of our study is that we have not conclu-
sively established a prevalence for ADTKD since we have
only sequenced UMOD as the most common underlying
mutation [2] and not MUC1 thought to be responsible
for 30% of ADTKD mutations. Furthermore our preva-
lence rates only apply to a predominantly Caucasian
population. Finally, the single centre design is a limita-
tion, although our tertiary renal centre covers a large
geographical mixed urban and rural area with a catch-
ment population of 2 million. While a multi-centric de-
sign would be preferable, this is the first and only
systematic study of the prevalence of ADTKD-UMOD
amongst patients with dominant renal disease. No na-
tional or international disease registry has been based on
a similar systematic approach, explaining the much
lower current numbers.
To minimise any distorting local factors such as re-
latedness of pedigrees, our prevalence rate for
ADTKD-UMOD of 9 per million was estimated conser-
vatively by counting each family only once. If we were to
count each affected patient instead, we would observe a
prevalence of ADTKD-UMOD of 17.5 per million and
of ADTKD of 30.5 per million.
We have shown that a simple questionnaire study on
family history combined with a database search followed
by genetic testing can uncover many additional cases of
genetic kidney diseases in general and ADTKD-UMOD
in particular.
Apart from incomplete and inadequate coding, the
reason for the low published prevalence rates appears
to be that genetic kidney diseases often go
unrecognized [21]. This is especially true for ADTKD
which has subtle phenotypic characteristics that can
easily be missed [15]. While genetic tests are available
for many genetic kidney diseases, they have not been
commonly performed historically, because of their
Table 3 UMOD mutation characteristics
Mutation Exon Protein alteration Wake Forest Registry HGMD Polyphen SIFT 1KG ESP ExAC
c.184A > Ca 3 p.(Thr62Pro) [34] Yesa No 0.662 0.030.03 0. – 0.0006.006 0.0004
c.202G > A 3 p.(Glu68Lys) [34] Yes No 0.999 0 – – –
c.263G > T 3 p.(Gly88Val) No No 1 0 – – –
c.272-274del 3 p.(Ser91del) [34] Yes No – – –
c.278_289delinsCCGCCTCCT 3 p.(Val93_Gly97delins
AlaAlaSerCys) [42]
Yes Yes – – –
c.443G > A 3 p.(Cys148Tyr) [10] Yes Yes 1 0.31 – – –
c.614 T > C 3 p.(Phe205Ser) No No 1 0 – – –
c.629G > A 3 p.(Gly210Asp) [34] Yes No 1 0 – – –
c.688 T > C 3 p.(Trp230Arg) [43] Yes Yes 1 0 – – –
c.860G > A 3 p.(Cys287Tyr) No No 1 0 – – –
c.917G > A 4 p.(Cys306Tyr) [34] Yes No 1 0 – – –
Mutation = UMOD mutation, Wake Forest Registry = inclusion in the Wake Forest School Registry of Inherited Kidney Diseases, HGMD = inclusion in the Human
Gene Mutation Database. Polyphen and SIFT = predictive scores of deleteriousness, 1 KG / ESP/ ExAC = occurrence in the large sequencing projects of populations
with European ancestry 1000 Genomes (1KG) and Exome Sequencing Project (ESP) and in 60,000 healthy individuals from varying ethnicities in the Exome
Aggregation Consortium (ExAC). aclinically silent
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cost and the limited availability of diagnostic centres.
Rare disease registries based on genetic results are
promising approaches but they still remain in their
infancy.
Looking for diagnostic clues, this study has
confirmed that clinical and biochemical tests need to
be interpreted with caution in the diagnosis of
ADTKD-UMOD. Since ADTKD-UMOD is a tubuloin-
terstitial disease, it is not surprising that it was
associated less often with haematuria and proteinuria
than other genetic kidney diseases, which included fa-
milial glomerulonephritides. Despite hyperuricaemia
Table 4 Comparison of clinical parameters between UMOD positive and negative patients with non-polycystic genetic kidney
diseases
Clinical parameter UMOD positive UMOD negative Significance level (p < 0.0036)
Age at presentation [years] 9–57, median 39, n = 21 0–80, median 35, n = 66 p = 0.882*
Age at RRT [years] 27–66, median 47, n = 27 9–84, median 41, n = 61 p = 0.116*
Gout 15/33 patients (45%) 30/78 (38%) p = 0.493**
Allopurinol use 13/35 patients (37%) 22/78 (28%) p = 0.342**
Hypertension at presentation 31/35 patients (89%) 69/78 (88%) p = 1.0***
Hyperuricaemia (Uric acid > 0.35 umol/l) 24/26 patients (92%) 50/61 patients (82%) p = 0.328***





Proteinuria 8/22 patients (36%) 48/62 patients (77%) p = 0.0004**
Protein Creatinine Ratio [mg/g] 0–2761, median 234.5,
n = 18
53–20,398, median = 2150,
n = 52
p < 0.001*
Anaemia pre RRT (Hb < 100 g/l) 4/27 patients (15%) 25/68 patients (37%) p = 0.036**
Microscopic haematuria 1/27 patients (4%) 24/63 patients (38%) p = 0.001**
Renal cysts 4/21 patients (19%) 6/51 patients (12%) p = 0.463***
Normal renal size at presentation
(renal diameter > 9 cm)
11/23 patients (48%) 30/48 patients (63%) p = 0.241**
Electrolyte abnormalities 6/32 patients (19%) 2/67 patients (3%) p = 0.013***
A Bonferroni correction was employed to adjust the significance level for the number of performed tests (i.e. the adjusted significance level is p < 0.05/14)
* = Mann Whitney U, ** = χ2, *** = Fisher’s Exact test
Table 5 Comparison of clinical parameters between UMOD positive and negative patients with ADTKD
Clinical parameter UMOD positive UMOD negative Significance level (p < 0.0036)
Age at presentation [years] 9–57, median 39, n = 21 23–80, median 49, n = 20 p = 0.024*
Age at RRT [years] 27–66, median 47, n = 27 27–83, median 51.5, n = 16 p = 0.606*
Gout 15/33 patients (45%) 10/25 patients (40%) p = 0.678**
Allopurinol use 13/35 patients (37%) 6/25 patients (24%) p = 0.281**
Hypertension at presentation 31/35 patients (89%) 22/25 patients (88%) p = 1.0***
Hyperuricaemia (Uric acid > 0.35 umol/l) 24/26 patients (92%) 15/19 patients (79%) p = 0.377***





Proteinuria 8/22 patients (36%) 6/17 patients (35%) p = 0.945**





Anaemia pre RRT (Hb < 100 g/l) 4/27 patients (15%) 7/22 patients (32%) p = 0.185***
Microscopic haematuria 1/27 patients (4%) 1/19 patients (5%) p = 1.0***
Renal cysts 4/21 patients (19%) 4/15 patients (27%) p = 0.694***
Normal renal size at presentation
(renal diameter > 9 cm)
11/23 patients (48%) 12/19 patients (63%) p = 0.32**
Electrolyte abnormalities 6/32 patients (19%) 1/22 patients (5%) p = 0.22***
* = Mann Whitney U, ** = χ2, *** = Fisher’s Exact test
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and gout being considered hallmarks of ADTKD-
UMOD, there was no significant association with the
disease, reflecting how common both are in a general
CKD population and that they can be absent in
ADTKD-UMOD [9]. Hyperuricaemia and/or gout can
still be helpful when present in patients with normal
renal function, especially in females and young
patients [15].
As we have shown, a positive family history remains
the most important diagnostic clue in the diagnosis of
ADTKD-UMOD and in genetic kidney diseases in gen-
eral. However, a family history may be absent in reces-
sive diseases, in de novo mutations and where a
relative’s kidney disease was either not diagnosed or
communicated to the rest of the family. While we recog-
nise these limitations, we have demonstrated the useful-
ness of a questionnaire on family history in uncovering
many undiagnosed genetic kidney diseases.
In our search for gene mutations, we performed
Sanger sequencing of the UMOD gene, a targeted next
generation sequencing panel of patients with FSGS/
SRNS [36], and exome sequencing of selected partici-
pants. In future, next generation sequencing techniques
such as (clinical) exome and whole genome sequen-
cing are expected to largely replace conventional se-
quencing. They deliver more genetic information in a
single assay and offer superior flexibility, as existing
sequencing data can be reviewed once new patho-
genic gene mutations become known. However, they
bring their own significant problems of the storage
and interpretation of large datasets and the interpret-
ation of multiple novel variants. Possible solutions in-
clude the segregation analysis of variants of interest,
functional studies and pooling of phenotype and
genotype data in national and international efforts
such as the 100,000 Genomes Project and RaDaR [24,
41]. The 31 study participants currently left with an
unknown familial nephropathy will be preferentially
recruited to the 100,000 Genomes Project to help un-
cover their underlying diagnoses which will help to
further inform our disease and prevalence data.
Conclusions
This study has demonstrated that the prevalence of
ADTKD, and ADTKD-UMOD in particular, is signifi-
cantly higher than previously reported. Due to
ADTKD’s lack of distinctive clinical features, clinical
suspicion should be aroused by a compatible family
history alone and should lead to genetic testing. As
shown, this approach is able to identify many previ-
ously unknown cases of ADTKD-UMOD, which can
benefit patients in terms of prognostication, the
provision of genetic counselling and the early identifi-
cation of affected relatives.
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